1. Prevention of birch pollen-related food allergy by mucosal treatment with multi-allergen-chimers in mice
- Author
-
Hoflehner, Elisabeth, Hufnagl, Karin, Schabussova, Irma, Jasinska, Joanna, Hoffmann-Sommergruber, Karin, Bohle, Barbara, Maizels, Rick M., and Wiedermann, Ursula
- Subjects
Proteomics ,Anatomy and Physiology ,Mouse ,lcsh:Medicine ,Protein Engineering ,T-Lymphocytes, Regulatory ,Cell Degranulation ,Epitopes ,Mice ,Immune Physiology ,lcsh:Science ,Betula ,Immunity, Cellular ,Mice, Inbred BALB C ,Allergy and Hypersensitivity ,Vaccination ,Animal Models ,Recombinant Proteins ,Basophils ,Cytokines ,Medicine ,Pollen ,Female ,Immunotherapy ,Food Hypersensitivity ,Research Article ,Immunology ,Peptide Mapping ,Immunomodulation ,Model Organisms ,Vaccine Development ,Immune Tolerance ,otorhinolaryngologic diseases ,Animals ,RNA, Messenger ,Antibodies, Blocking ,Biology ,Administration, Intranasal ,lcsh:R ,Immunity ,Immunoregulation ,Allergens ,Antigens, Plant ,Immunoglobulin E ,Immunity, Humoral ,Nasal Mucosa ,Gene Expression Regulation ,Clinical Immunology ,Immunization ,lcsh:Q - Abstract
Background Among birch pollen allergic patients up to 70% develop allergic reactions to Bet v 1-homologue food allergens such as Api g 1 (celery) or Dau c 1 (carrot), termed as birch pollen-related food allergy. In most cases, specific immunotherapy with birch pollen extracts does not reduce allergic symptoms to the homologue food allergens. We therefore genetically engineered a multi-allergen chimer and tested if mucosal treatment with this construct could represent a novel approach for prevention of birch pollen-related food allergy. Methodology BALB/c mice were poly-sensitized with a mixture of Bet v 1, Api g 1 and Dau c 1 followed by a sublingual challenge with carrot, celery and birch pollen extracts. For prevention of allergy sensitization an allergen chimer composed of immunodominant T cell epitopes of Api g 1 and Dau c 1 linked to the whole Bet v 1 allergen, was intranasally applied prior to sensitization. Results Intranasal pretreatment with the allergen chimer led to significantly decreased antigen-specific IgE-dependent β-hexosaminidase release, but enhanced allergen-specific IgG2a and IgA antibodies. Accordingly, IL-4 levels in spleen cell cultures and IL-5 levels in restimulated spleen and cervical lymph node cell cultures were markedly reduced, while IFN-γ levels were increased. Immunomodulation was associated with increased IL-10, TGF-β and Foxp3 mRNA levels in NALT and Foxp3 in oral mucosal tissues. Treatment with anti-TGF-β, anti-IL10R or anti-CD25 antibodies abrogated the suppression of allergic responses induced by the chimer. Conclusion Our results indicate that mucosal application of the allergen chimer led to decreased Th2 immune responses against Bet v 1 and its homologue food allergens Api g 1 and Dau c 1 by regulatory and Th1-biased immune responses. These data suggest that mucosal treatment with a multi-allergen vaccine could be a promising treatment strategy to prevent birch pollen-related food allergy.
- Published
- 2012